Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02301039
Title A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Alliance for Research through Collaboration
Indications

malignant peripheral nerve sheath tumor

liposarcoma

medulloblastoma

synovial sarcoma

leiomyosarcoma

fibrous histiocytoma

Therapies

Pembrolizumab

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.